23 articles for ML Curtin
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.
Abbvie
A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units.
Abbott Laboratories
Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC).
Abbott Laboratories
Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases.
Abbott Laboratories
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.
Abbott Laboratories
7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Abbott Laboratories
Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase.
Abbott Laboratories
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
Abbott Laboratories
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
Abbott Laboratories
Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.
Abbott Laboratories
The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.
Abbott Laboratories
Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.
Abbott Laboratories
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
Abbott Laboratories
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Abbvie
Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors
Merck Sharp & Dohme